Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011 ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are tirzepatide (Zepbound) and semaglutide (Wegovy). Semaglutide was originally ...

Diabetes Care. 2006;29(2):435-449.

Pfizer Inc. (NYSE: PFE) today announced the decision to discontinue development of danuglipron (PF-06882961), an oral ...

Treatment with glucagon-like peptide-1 receptor agonists (GLP-1RAs) may reduce the risk of dementia or cognitive impairment.

HANOI, VIETNAM / ACCESS Newswire / April 14, 2025 / Together with world-renowned scientists including Prof. Joel F. Habener, ...

Finding natural ways to increase glucagon-like peptide-1, otherwise known as GLP-1, can be very beneficial in helping treat ...

Morbidly obese patients remain an unsolved clinical problem,” explained co-author Gwo-Chin Lee, M.D., a hip and knee replacement surgeon at HSS. “Traditional weight loss measures have had mixed ...

HANOI, VIETNAM - Media OutReach Neswire - 14 April 2025 - Together with world-renowned scientists including Prof. Joel F. Habener, Prof. Jens Juul Holst and Assoc. Prof. Svetlana Mojsov, Prof. Daniel ...

Shares of Viking Therapeutics have sold off sharply as the market awaits updates on its drug candidates. The company is preparing for the possible FDA approval of its weight loss drug candidate VK2735 ...

Shares of Viking Therapeutics (VKTX) and Structure Therapeutics (GPCR) are on the rise on Monday after Pfizer (PFE) announced its decision to ...

In this retrospective cohort study, tirzepatide dispensations were found to have increased significantly following approval ...